Our Experience in Cell & Gene Therapy

MCRA’s Cell and Gene Therapy Team provides expert regulatory strategy and clinical development consulting support relating to advanced therapies through development to commercialization. Core product focus areas include:

  • Cell Therapies

  • Gene Therapies

  • Exosomes

  • Delivery Devices

  • Combination Products

  • Companion Diagnostics

  • Advanced Manufacturing

  • Breakthrough and RMAT Designations

  • Rare Diseases

  • Biologics Quality & Compliance

 

Contact a Cell & Gene Therapy Expert

 

Meet Our Cell & Gene Therapy Team

Led by predominant leaders in the field with over two decades of FDA regulatory experience, MCRA's Cell & Gene Therapy team bring their experience and deep insight of the innerworkings of the Center for Biologics Evaluation and Research (CBER) policy and regulatory review to MCRA’s clients to effectively navigate this complex regulatory framework. Meet our expert team below. 

View Contact
Carolyn Yong, Ph.D.

Carolyn Yong, Ph.D.

Vice President, Regenerative Medicine and Biologics Quality
View Contact
Iris Marklein, Ph.D.

Iris Marklein, Ph.D.

Senior Director, Regulatory Affairs – Regenerative Medicine & Biologics Quality